COGS

Cantaloupe, Inc. Reports Third Quarter Fiscal Year 2024 Financial Results

Retrieved on: 
Donnerstag, Mai 9, 2024
Software, Other Retail, Data Management, Technology, Apps, Applications, Online Retail, Retail, Other Technology, Education, Seed, PIN, Sport, ARPU, Depreciation, P30, CHEQ, Tax, Adjustment, COGS, GAAP, Growth, Video game

Cantaloupe, Inc. (Nasdaq: CTLP) (“Cantaloupe” or the “Company”), a leading provider of end-to-end technology solutions for self-service commerce, today reported results for the third quarter ended March 31, 2024.

Key Points: 
  • Cantaloupe, Inc. (Nasdaq: CTLP) (“Cantaloupe” or the “Company”), a leading provider of end-to-end technology solutions for self-service commerce, today reported results for the third quarter ended March 31, 2024.
  • “In the third quarter, we reported strong results, reflecting our continued expansion of operating leverage by driving revenue growth while also optimizing COGS and controlling operational expenses.
  • Third Quarter 2024 Business Highlights:
    Active Customers totaled 30,670 at the end of the third quarter of 2024 compared to 27,598 at the end of the third quarter of 2023, an increase of 11.1%.
  • Active Devices totaled 1.22 million at the end of the third quarter of 2024 compared to 1.15 million at the end of the third quarter of 2023, an increase of 5.9%.

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Donnerstag, Mai 9, 2024
CVR, CHRS, FDA, GAAP, TSA, Total, NCCN, Investment, Ophthalmology, Conference call, Research, CRI, Conference, ADCC, Exercise, Cancer Research Institute, Medicare Advantage, Acquisition, NPC, Medicare, COGS, Ovarian cancer, Relative value unit, Pharmaceutical industry

REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for the quarter ended March 31, 2024 and recent business highlights: 

Key Points: 
  • Total unit demand grew 36% in Q1 2024 compared to Q4 2023 and represented a 108% increase compared to Q1 2023.
  • Based on data from IQVIA, UDENYCA franchise market share for Q1 2024 was 25%, an increase of 10 market share points in Q1 2024 compared to Q4 2023.
  • LOQTORZI, the first and only FDA-approved treatment for recurrent, locally advanced or metastatic NPC, commercially launched on January 2, 2024.
  • Coherus projects combined R&D and SG&A expenses for 2024 to be in the range of $250 to $265 million.

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Retrieved on: 
Dienstag, Mai 7, 2024
FDA, VLA, Bank statement, Fast Track, Research, CHMP, Trial of the century, Biologics license application, Coalition, Profit & Loss, OrbiMed, Lyme disease, Bavarian Nordic, CDC, Notifiable disease, Adolescence, Income tax, Chikungunya, Third party, ACIP, BLA, Licensure, CEPI, PRV, Safety, Travel, Indoor Living, EMA, Marketing, USD, Sale, Tropical disease, EDT, Depreciation, MAA, Profit, Euronext Paris, Zika virus, Epidemic, Adjustment, COGS, Saint-Herblain, COVID-19, Growth, Ageing

Saint-Herblain (France), May 7, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2024, and provided corporate updates.

Key Points: 
  • Saint-Herblain (France), May 7, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2024, and provided corporate updates.
  • The condensed consolidated interim financial results are available on the Company’s website ( Financial Reports – Valneva ).
  • In the first quarter of 2024, IXIARO®/JESPECT® sales were €16.6 million compared to €17.4 million in the first quarter of 2023.
  • IXIARO®/JESPECT® sales were €16.6 million in the first quarter of 2024 compared to €17.4 million in the first quarter of 2023.

Axon reports Q1 2024 revenue of $461 million, up 34% year over year, raises outlook

Retrieved on: 
Montag, Mai 6, 2024
Cloud, Metadata, Total, Ecosystem, Aircraft, Investment, Virtual reality, Risk, Law enforcement, Partnership, Artificial intelligence, Police, Attention, Albuquerque Police Department, VR, Ethics, App Store (iOS/iPadOS), Simulation, Felony, Acquisition, Sensor, Adjustment, Generative, COGS, Letter, Philosophy, Growth, Video game

Axon Cloud & Services revenue of $176 million grew 52% year over year, more than doubling over the last two years.

Key Points: 
  • Axon Cloud & Services revenue of $176 million grew 52% year over year, more than doubling over the last two years.
  • Sensors & Other revenue of $106 million grew 14% year over year driven by adoption of Axon Body 4.
  • Looking ahead, we aim to deliver improved financial performance and are increasing our revenue and Adjusted EBITDA expectations for the year.
  • In April, we hosted our ninth annual user conference, combining our long-running Axon Accelerate and second annual TASERCON into one main event — Axon Week.

Pegasus Biotech Announces Filing of Provisional Patent Application for BPE Plasmid Technology

Retrieved on: 
Montag, Mai 6, 2024
DNA, COGS, BPE, Fermentation

CHARLOTTETOWN, PE, May 6, 2024 /PRNewswire-PRWeb/ -- Pegasus Biotech has announced the filing of a provisional patent application for their new BPE plasmid technology.

Key Points: 
  • CHARLOTTETOWN, PE, May 6, 2024 /PRNewswire-PRWeb/ -- Pegasus Biotech has announced the filing of a provisional patent application for their new BPE plasmid technology.
  • This novel technology is a high-yielding, ultra-low-cost, selection marker free plasmid that has the potential to significantly reduce plasmid manufacturing COGS.
  • The technology has been demonstrated to have greater than 1.25 g/L plasmid fermentation yields with plasmid copy numbers in excess of 1000 copies/cell.
  • The technology has the added benefit of having enhanced expression, with cells transfected with BPE plasmid having up to 7X the expression of conventional plasmid backbones.

American Aires Announces Record Q4 and Annual 2023 Order Volume and Significant Q4 EBITDA Profitability

Retrieved on: 
Freitag, April 12, 2024
Sale, EMF, ROI, Conversation, Social media, Health, Management, Marketing, Yoy, MD, Partnership, Financial statement, Development, Electromagnetic radiation, Athlete, OTC Markets Group, Advertising, COGS, Growth, Cryptocurrency

The Aires team is proud of its Q4 2023 performance, achieving record order volume of $3.7 million,1 largely due to enhancements made to Aires' marketing and advertising strategy.

Key Points: 
  • The Aires team is proud of its Q4 2023 performance, achieving record order volume of $3.7 million,1 largely due to enhancements made to Aires' marketing and advertising strategy.
  • The record level of quarterly order volume was achieved despite a temporary shortage of product that limited sales.
  • The Company drove an impressive order volume increase of 79% YoY to $10.4 million (up from $5.8 million in 2022).
  • The strong order volume financial results are a direct result of the brand-building vision of American Aires CEO, Josh Bruni, and his ability to consistently drive growth, such as 2022's order volume increase of 128% YoY.

Cleo Introduces New Order Automation Solution for Suppliers

Retrieved on: 
Dienstag, April 30, 2024
Technology, Transport, Electronic Commerce, Software, Internet, Logistics, Supply Chain Management, Retail, Data Management, Cloud, Ecosystem, E-commerce, ERP, B2C, Workflow, EDI, CIC, Automation, Multimedia, COGS, Government, Growth, Online shopping

View the full release here: https://www.businesswire.com/news/home/20240430491853/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240430491853/en/
    CIC ORCA (for Order-to-Cash Automation) is a strategic extension of Cleo Integration Cloud (CIC), Cleo’s ecosystem integration platform which is already in use at more than 4,200+ companies worldwide.
  • In an era shaped by the “Amazon Effect,” suppliers are increasingly expected to emulate the B2C buying experience.
  • “Order automation is a critical must-have for every manufacturer, wholesaler or distributor doing business today.
  • For sellers, CIC ORCA offers a seamless gateway for Order-to-Cash automation – translating B2B eCommerce orders into EDI transactions to directly integrate them into back-office ERP systems.

Armanino Foods of Distinction, Inc. Reports the Highest First Quarter Profits in Company’s History

Retrieved on: 
Dienstag, April 23, 2024
Retail, Supermarket, Food, Beverage, Cheese, Investment, Garlic, History, Tax, Eye, OTC Markets Group, COGS, Artichoke, Pharmaceutical industry

Armanino Foods of Distinction, Inc. (OTC Pink: AMNF) reported its highest quarterly profits ever for the first quarter ending March 31, 2024.

Key Points: 
  • Armanino Foods of Distinction, Inc. (OTC Pink: AMNF) reported its highest quarterly profits ever for the first quarter ending March 31, 2024.
  • Net sales for the first quarter of 2024 were $15,720,317 compared to $16,351,866 for the same period last year, a decrease of 4%.
  • Income before taxes for Q1 2024 was $3,116,504 compared to $2,561,406 for the same quarter in 2023, an increase of 22%.
  • Tim Anderson, President and CEO, stated, “We continue to benefit from our margin improvement efforts as demonstrated by achieving the highest first quarter profits and second highest profits for a quarter.

AI in Healthcare: Unveiling the Future with a 42.20% CAGR Through 2029

Retrieved on: 
Donnerstag, April 25, 2024
Enzyme, MedShare, KPI, Health equity, Tech, AI, OTC, Machine learning, Software, Health care, Business development, Partnership, Alchemy, Ginkgo, Recursion, API, Business, Artificial intelligence, Intelligence, Roche, Nvidia, Ginkgo Bioworks, Gold, DNA, Microsoft, HCAT, Ninja, Research report, Patient, Acquisition, MSFT, Platform, Professional services, NEO, Reverie, COGS, Drug discovery, Organization, Health, Medical device

VANCOUVER, BC, April 25, 2024 /PRNewswire/ -- Across several sectors the use of artificial intelligence (AI) is making a huge impact, with healthcare emerging as possibly receiving the largest boost. According to a new research report from analysts at Mordor Intelligence, the market for artificial intelligence in health care is set to explode at a CAGR of 42.20% through 2029. As the tech sector races to provide the market with solutions, several companies are emerging as leaders in aiding the healthcare sector, including Avant Technologies Inc. (OTC:AVAI), Microsoft Corporation (NASDAQ:MSFT) (NEO:MSFT), Health Catalyst, Inc. (NASDAQ:HCAT), Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), and Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX).

Key Points: 
  • This network will offer big data and AI software companies a quicker, more potent, and more affordable computing infrastructure.
  • The goal of this deal is to bring together Avant Technologies and Wired-4-Health to improve how healthcare data is shared and used.
  • Microsoft is enhancing its Azure AI Health Bot services by adding new healthcare-specific safeguards and features, including integration with Microsoft Copilot Studio.
  • Last year, Recursion lined up a $50-million collaboration with AI chipmaking giant Nvidia for AI drug discovery.

AI in Healthcare: Unveiling the Future with a 42.20% CAGR Through 2029

Retrieved on: 
Donnerstag, April 25, 2024
Enzyme, MedShare, KPI, Health equity, Tech, AI, OTC, Machine learning, Software, Health care, Business development, Partnership, Alchemy, Ginkgo, Recursion, API, Business, Artificial intelligence, Intelligence, Roche, Nvidia, Ginkgo Bioworks, Gold, DNA, Microsoft, HCAT, Ninja, Research report, Patient, Acquisition, MSFT, Platform, Professional services, NEO, Reverie, COGS, Drug discovery, Organization, Health, Medical device

VANCOUVER, BC, April 25, 2024 /PRNewswire/ -- Across several sectors the use of artificial intelligence (AI) is making a huge impact, with healthcare emerging as possibly receiving the largest boost. According to a new research report from analysts at Mordor Intelligence, the market for artificial intelligence in health care is set to explode at a CAGR of 42.20% through 2029. As the tech sector races to provide the market with solutions, several companies are emerging as leaders in aiding the healthcare sector, including Avant Technologies Inc. (OTC:AVAI), Microsoft Corporation (NASDAQ:MSFT) (NEO:MSFT), Health Catalyst, Inc. (NASDAQ:HCAT), Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), and Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX).

Key Points: 
  • This network will offer big data and AI software companies a quicker, more potent, and more affordable computing infrastructure.
  • The goal of this deal is to bring together Avant Technologies and Wired-4-Health to improve how healthcare data is shared and used.
  • Microsoft is enhancing its Azure AI Health Bot services by adding new healthcare-specific safeguards and features, including integration with Microsoft Copilot Studio.
  • Last year, Recursion lined up a $50-million collaboration with AI chipmaking giant Nvidia for AI drug discovery.